|Year : 1990 | Volume
| Issue : 1 | Page : 34-36
Treatment of acne vulgaris with anti androgens
Neena Vaswani, RK Pandhi
This study was conducted to compare the relative efficacy of spironolactone and cimetidine in moderately severe acne vulgaris. Fifteen women were treated with spironolactone (100 mg daily) given cyclically, while 14 women were given cimetidine (1400 mg daily) cyclically. The response was evaluated at 12 weeks. Spironolactone produced a good to excellent response in 11 (73. 3%) acne patients while with cimetidine 6 (42.8%) patients showed a good to excellent response. The mean reduction of the non-inflammatory and inflammatory lesion count was 29. 3 + 3. 6 and 9. 7 + 1. 3 respectively with spironolactone and 18.6 + 5.8 and 6.4 + 2.1 respectively with cimetidine. The response of acne vulgaris to spironolactone was superior to that of cimetidine and this difference was statistically significant (p<.05). The side effects were minimal and did not necessitate withdrawal of treatment.
|How to cite this article:|
Vaswani N, Pandhi R K. Treatment of acne vulgaris with anti androgens.Indian J Dermatol Venereol Leprol 1990;56:34-36
|How to cite this URL:|
Vaswani N, Pandhi R K. Treatment of acne vulgaris with anti androgens. Indian J Dermatol Venereol Leprol [serial online] 1990 [cited 2019 Dec 8 ];56:34-36
Available from: http://www.ijdvl.com/text.asp?1990/56/1/34/3476
Androgens are known to stimulate sebaceous gland activity and the appearance of acne is partly linked to the rising levels of androgens that occur at puberty. It is thus logical to use anti-androgens for the treatment of acne.
Cyproterone acetate has been successfully used for the treatment of acne and hirsutism., Spironolactone and cimetidine also have antiandrogenic properties and have been successfully used for the treatment of hirsutism. Recently, spironolactone has also been found useful for the treatment of acne both systemically, and topically. Buckshee and Ahuja observed that cimetidine reduced acne and facial oiliness, but the response was not graded. To the best of our knowledge, the relative efficacy of spironolactone and cimetidine has not been compared in acne.
Materials and Methods
Thirty two women (aged 12-25 years) with moderately severe acne were taken up for the study. Moderately severe acne was defined as presence of 5-15 inflammatory lesions and/or more than 50 non-inflammatory lesions. Patients who had hirsutism and women who were either pregnant or using oral contraceptives were not included. Patients who were taking oral antibiotic therapy were included only one month after discontinuing the antibiotics.
Patients were randomly allocated to one of the two treatment schedules : (a) Spironolactone, 100 mg a day or (b) cimetidine, 1400 mg a day given from the fifth to twenty fifth day of the menstrual cycle in patients with regular cycles and for twenty one days with a seven day gap in patients with irregular cycles.
No local therapy was prescribed with either of the two schedules. The blood pressure and the serum electrolyte (sodium and potassium) levels were regularly monitored.
The efficacy of the drugs was evaluated at 4 weekly intervals by counting the lesions by the same observer. The criterion for effectiveness of the treatment was significant reduction in the number of non-inflammatory and inflammatory lesions on the face at the end of 12 weeks. The improvement was graded as follows : (1) excellent, when there was more than 75% reduction in the lesion count, (2) good, when there was 50-75% reduction in the lesion count, (3) fair, when there was 25-50% reduction in the lesion count, (4) poor, when there was less than 25% reduction in the lesion count.
In addition, the mean reduction in noninflammatory and inflammatory lesions was calculated for each of the two therapeutic groups. The response was statistically evaluated using Student's t-test. A p value of 2 receptor blocker, decreases the binding of dihydrotestosterone to the androgen receptors.
In the present study, spironolactone produced a good to excellent improvement in 11 (73.3%) acne patients, while 2 (13.3%) patients showed a poor response. The mean reduction of the non-inflammatory lesions was 29.3 + 3.6, and of the inflammatory lesions 9.7 + 1.3. These results are similar to those of Muhlemann et al. They had used a higher dose (200 mg) of spironolactone in 21 women with acne vulgaris for 3 months and noted a significant improvement in 75% of their patients. Goodfellow et al found spironolactone effective in 16 patients with severe acne in doses of 50-200 mg daily; the clinical response was found to be dose dependent, with the maximum benefit in a dose of 150-200 mg. They also found a dose dependent reduction in the excretion rate of sebum in these patients.
The side effects noted by us are similar to those observed by Muhlemann et al. Goodfellow et al, however, noted a higher incidence of side effects, because they had included male patients in their study.
Buckshee and Ahujas used cimetidine for the treatment of hirsutism and noticed a concomitant improvement in acne in their subjects. They however did not quantify the response. We found good to excellent response to cimetidine in 6 (42.8%) patients of acne while 5 (35.7%) showed a poor response. The lesion count showed a mean reduction of 18.6 + 5.8 and 6.4 + 2.1 for the non-inflammatory and inflammatory lesions respectively.
The incidence of side-effects of cimetidine in our patients and the type of untoward effects are similar to those observed by Buckshee and Ahuja.
A better response with spironolactone than cimetidine, seems logical, because in vitro studies have shown that spironolactone is a more potent androgen receptor blocker than both cyproterone acetate and cimetidine. The therapeutic effect of these two anti-androgens has previously not been compa red in acne.
|1||Hammerstein J, Mechies J, Leo R et al Use of cyproterone acetate in the treatment of acne, hirsutism and virilism, J Steroid Biochem, 1975; 6 : 827-836.|
|2||Ekoe J, Burckhardt P and Ruedi S : Treatment of hirsutism, acne and alopecia with cyproterone .acetate, Dennatologica, 1980; 160 : 398-404.|
|3||Cumming DG, Yaug JC, Rebar RW et al : Treatment of hirsutism with spironolactone, J Amer Med Assoc, 1982; 247 : 1295-1298.|
|4||Funder JW and Mercer JR : Cimetidine, a histamine H2 receptor antagonist occupies androgen receptors, J Clin Endocrinol Metabol, 1979; 48 189-191.|
|5||Buckshee K, Kaur J, Agarwal N et al : Therapeutic evaluation of spironolactone and cimetidine in hirsutism, J Obstet Gyraecol, 1987; 27 : 423-426.|
|6||Goodfellow A, Alaghband-Zadeh J, Carter G et al : Oral spironolactone improves acne vulgaris and reduces sebum excretion, Brit J Dermatol, 1984; 111 : 209-214.|
|7||Muhlemann MF, Carter GD, Cream JJ and Wise P : Oral spironolactone : an effective treatment for acne vulgaris in women, Brit J Dermatol, 1986; 115 : 227-232.|
|8||Messina M : A new therapeutic approach to treatment of acne, Cur Therap Res, 1983; 34 319-323.|
|9||Buckshee K and Ahuja MMS : Therapeutic evaluation of effectiveness of cimetidine in the treatment of hirsutism, Ind J Med Res, 1985; 82 562-564.|
|10||Biffignandi P, Massucchettic and Mounatti GM Free estradiol increase with concomitant decrease of free testosterone in plasma from normal men after incubation with spironolactone, Horm Metabol Res, 1983; 15 : 55-58.|
|11||EI C and Edelsen SK : The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors, J Clin Endocrinol Metabol, 1984; 59 : 51-57.|